MCID: PSR002
MIFTS: 65

Psoriasis

Categories: Rare diseases, Skin diseases, Genetic diseases

Aliases & Classifications for Psoriasis

MalaCards integrated aliases for Psoriasis:

Name: Psoriasis 12 72 49 36 28 51 40 3 14 69 59

Classifications:



External Ids:

Disease Ontology 12 DOID:8893
ICD10 32 L40 L40.9
MeSH 41 D011565
NCIt 46 C3346
KEGG 36 H01656
UMLS 69 C0033860

Summaries for Psoriasis

MedlinePlus : 40 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast. Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include Infections Stress Dry skin Certain medicines Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Psoriasis is related to guttate psoriasis and pustular psoriasis, and has symptoms including psoriasiform rash, pruritus and exanthema. An important gene associated with Psoriasis is PSORS5 (Psoriasis Susceptibility 5). The drugs Rayos and Zinc have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells.

NIH Rare Diseases : 49 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. The skin on the elbows, knees, scalp, back, face, palms and feet is most often affected, but other parts of the body can be affected as well. A problem with the immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in the skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because the cells rise too fast. Although symptoms may come and go, for many, psoriasis is a lifelong condition. Infections, stress, dry skin and certain medications may make symptoms worse. Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medications and light therapy. Last updated: 7/11/2016

CDC : 3 Psoriasis causes patches of thick red skin and silvery scales. Patches are typically found on the elbows, knees, scalp, lower back, face, palms, and soles of feet, but can affect other places (fingernails, toenails, and mouth). The most common type of psoriasis is called plaque psoriasis.Psoriatic arthritis is an inflammatory type of arthritis that eventually occurs in 10% to 20% of people with psoriasis. It is different from more common types of arthritis (such as osteoarthritis or rheumatoid arthritis) and is thought to be related to the underlying problem of psoriasis. Psoriasis and psoriatic arthritis are sometimes considered together as psoriatic disease.

PubMed Health : 59
About psoriasis: Psoriasis is a non-contagious inflammatory disease. The main symptoms are reddish, scaly patches of skin that may itch.It is a chronic condition that is typically associated with periods of more severe skin problems (flare-ups) followed by periods of milder skin problems or none at all. Various treatments can relieve the symptoms, but there is no cure for psoriasis.Its severity can vary quite a lot. In some people it is bothersome more than anything else, and they can cope with it quite well. Others feel that it has a major effect on their quality of life, since the treatment and skin care can take a long time. Many people are also unhappy about having visible reddened and scaly skin patches – especially if they are on exposed areas of their body.Sometimes the inflammation that is causing the psoriasis affects other parts of the body too, such as the joints or nails.

Wikipedia : 72 Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. These skin... more...

Related Diseases for Psoriasis

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13

Diseases related to Psoriasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 510)
# Related Disease Score Top Affiliating Genes
1 guttate psoriasis 34.8 CDSN HLA-C
2 pustular psoriasis 34.8 CARD14 IL36RN TNF
3 pustulosis of palm and sole 34.0 IL36RN TNF
4 pustulosis palmaris et plantaris 33.9 IL36RN TNF
5 impetigo herpetiformis 33.3 CARD14 IL36RN
6 geographic tongue 33.1 HLA-C IL36RN TNF
7 skin disease 31.5 CARD14 CDSN IL36RN TNF
8 pityriasis rubra pilaris 31.1 CARD14 IL36RN
9 glossitis 30.8 KRT17 TNF
10 psoriasis 14, pustular 12.6
11 psoriasis 1 12.5
12 psoriasis 7 12.3
13 psoriasis 11 12.3
14 psoriasis 13 12.3
15 psoriasis 2 12.3
16 psoriatic arthritis 12.2
17 psoriasis 15, pustular 12.1
18 psoriasis 4 12.0
19 psoriasis 5 12.0
20 psoriasis 6 12.0
21 psoriasis 9 12.0
22 psoriasis 3 11.9
23 psoriasis 8 11.9
24 psoriasis 10 11.9
25 psoriasis 12 11.9
26 mental retardation and psoriasis 11.9
27 psoriatic juvenile idiopathic arthritis 11.6
28 tranebjaerg svejgaard syndrome 11.6
29 arthritis 11.3
30 parapsoriasis 11.3
31 subacute cutaneous lupus erythematosus 11.1
32 chronic recurrent multifocal osteomyelitis 11.1
33 singleton-merten syndrome 1 10.9
34 systemic onset juvenile idiopathic arthritis 10.9
35 peeling skin syndrome 10.8 CCHCR1 CDSN PSORS1C1
36 nail disorder, nonsyndromic congenital, 1 10.8
37 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.8
38 singleton-merten syndrome 2 10.8
39 temporomandibular ankylosis 10.8
40 primary cutaneous amyloidosis 10.8
41 singleton-merten syndrome 10.8
42 sympathetic ophthalmia 10.7 HLA-C TNF
43 trachoma 10.7 HLA-C TNF
44 sialadenitis 10.6 CDSN TNF
45 hematopoietic stem cell transplantation 10.5 HLA-C TNF
46 dermatitis 10.4
47 lacrimal apparatus disease 10.4 CDSN TNF
48 dermatitis, atopic 10.3
49 endotheliitis 10.2
50 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1

Graphical network of the top 20 diseases related to Psoriasis:



Diseases related to Psoriasis

Symptoms & Phenotypes for Psoriasis

UMLS symptoms related to Psoriasis:


psoriasiform rash, pruritus, exanthema

Drugs & Therapeutics for Psoriasis

PubMedHealth treatment related to Psoriasis: 59

There are various treatment options for psoriasis:Basic therapy (skin care): Care of the affected areas of skin using lipid-replenishing ointments, creams or lotions. This is done to keep the skin supple, protect it from injury and relieve itching. Some products also contain medications that are supposed to reduce shedding, such as urea or salicylic acid.Topical treatment: Products containing corticosteroids or vitamin D analogues are typically used in topical treatment (treatment applied to the skin from the outside). These are available in the form of creams, ointments lotions or foams.Light therapy: Light therapy, also known as phototherapy, involves exposing the plaques to ultraviolet light (UV light). The UV light reduces inflammation in the skin, and also slows the production of cells. Sometimes medications called psoralens are used in combination with light therapy. Psoralens make the skin more sensitive to light. Light therapy is best suited for people who have moderate or severe psoriasis and in whom topical treatment alone wasn't effective enough.Medications that are taken orally or injected: These medicines are a treatment option for moderate or severe psoriasis. They inhibit the body's immune response. Methotrexate (MTX), fumaric acid esters, apremilast and biological drugs (biologics) are commonly used for this purpose.Basic moisturizing skin care is always recommended for psoriasis – during periods without any skin problems, too.There are also many herbal medicines for the treatment of psoriasis, including extracts of barberry (Mahonia aquifolium), birch bark or aloe vera. The effectiveness of these herbal medicines hasn't been tested in any good-quality studies, though. So it isn't known whether they can help.Some studies suggest that people with psoriasis who are overweight can improve the condition of their skin by losing a few pounds.It is sometimes claimed that a tonsillectomy (removal of the tonsils) can relieve psoriasis symptoms, but there hasn't been much research in this area. Tonsillectomy usually isn't recommended because the operation may cause complications such as infections, bleeding and changes to the person's voice. There are also no studies showing that having your tonsils out can cure or prevent psoriasis.

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Rayos 17 PREDNISONE Horizon Pharma July of 2012

Drugs for Psoriasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 425)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 32051 23994
2
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
3
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
4
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 185243-69-0
5
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 378-44-9 9782
6
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Acitretin Approved Phase 4,Phase 3,Phase 2 55079-83-9 5284513 6437841
9
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 5271565 637568
10
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
12
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
13
Desonide Approved, Investigational Phase 4 638-94-8 5311066
14
Ustekinumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 815610-63-0
15
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
16
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 657311 5754
19
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
20
Triamcinolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 124-94-7 31307
21
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
22
Tazarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 118292-40-3 5381
23
Desoximetasone Approved Phase 4,Phase 3,Phase 2 382-67-2 5311067
24
Clocortolone Approved Phase 4 4828-27-7, 34097-16-0 5311052 5282493
25
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 93-14-1 3516
26
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 608141-41-9 11561674
27 Racepinephrine Approved Phase 4,Phase 2 329-65-7
28
Anthralin Approved Phase 4 1143-38-0
29
Clobetasol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 25122-41-2, 25122-46-7 5311051 32798
30
Dapsone Approved, Investigational Phase 4 80-08-0 2955
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
34
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 32222-06-3 5280453 134070
35 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
37
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3 59-67-6 938
38
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
39
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3 98-92-0 936
40
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
41
Butyric Acid Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107-92-6 264
42 beta-endorphin Phase 4
43 Amotosalen Phase 4,Phase 2,Early Phase 1
44 Betamethasone Valerate Phase 4,Phase 3,Phase 2,Phase 1 2152-44-5
45 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
46 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
47 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Ficusin Phase 4,Phase 2,Early Phase 1
49 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1397)

# Name Status NCT ID Phase Drugs
1 The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
2 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate Unknown status NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
3 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
4 Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
5 Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis Unknown status NCT02144857 Phase 4 etanercept;ustekinumab;cyclosporine
6 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
7 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
8 Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
9 Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
10 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
11 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
12 A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
13 The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
14 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
15 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
16 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
17 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
18 An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis Completed NCT01555606 Phase 4
19 Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray Completed NCT02985736 Phase 4 Topicort Topical Spray
20 Topical Psoriasis Study for Patients Receiving Biologic Therapy Completed NCT02983981 Phase 4 Topicort Topical Spray
21 A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries Completed NCT01677598 Phase 4 No intervention
22 Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis Completed NCT00924950 Phase 4 Taclonex Ointment and Hydrogel Patch;Taclonex Ointment
23 A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4 TINEFCON
24 Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis Completed NCT01012713 Phase 4 Clobex Spray;Vectical Ointment
25 Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis Completed NCT01039142 Phase 4 Acitretin
26 Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis Completed NCT00990561 Phase 4 Ultravate ointment twice daily + LacHydrin lotion twice daily;Ultravate ointment once daily + LacHydrin lotion twice daily
27 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
28 Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
29 A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
30 Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Completed NCT00992394 Phase 4 etanercept;etanercept
31 Clinical Assessment and Psychosocial Impact of Psoriasis Completed NCT01964443 Phase 4
32 The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment Completed NCT01511315 Phase 4 Ustekinumab
33 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
34 A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis. Completed NCT01262534 Phase 4
35 A Study of Efalizumab in Patients With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies Completed NCT00249808 Phase 4 Efalizumab - anti CD11a recombinant human monoclonal antibody
36 Comparison Study of Psoriasis Severity Assessment Tools Completed NCT02655705 Phase 4 Cyclosporine A;Methotrexate
37 Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis Completed NCT00936065 Phase 4 Etanercept;Etanercept + Acitretin;Acitretin
38 Apremilast in Palmo-Plantar Psoriasis Completed NCT02400749 Phase 4 Apremilast;Placebo
39 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
40 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis Completed NCT01265823 Phase 4
41 Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A Completed NCT02547714 Phase 4 Secukinumab (AIN457)
42 Adalimumab-psoriasis and Small Bowel Lesions Completed NCT01556672 Phase 4 Adalimumab
43 A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp Completed NCT00669214 Phase 4 efalizumab;placebo
44 Moderate to Severe Plaque Psoriasis With Scalp Involvement Completed NCT00791765 Phase 4
45 Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp Completed NCT00881868 Phase 4 clobetasol propionate spray 0.05%;Vehicle spray
46 Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects Completed NCT00658606 Phase 4 alefacept
47 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet Completed NCT00735787 Phase 4
48 Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis Completed NCT00655564 Phase 4 Alefacept
49 Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
50 Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis Completed NCT00723437 Phase 4 acitretin

Search NIH Clinical Center for Psoriasis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Psoriasis

Genetic tests related to Psoriasis:

# Genetic test Affiliating Genes
1 Psoriasis 28

Anatomical Context for Psoriasis

MalaCards organs/tissues related to Psoriasis:

38
Skin, Testes, T Cells, Endothelial, Liver, Neutrophil, Monocytes

Publications for Psoriasis

Articles related to Psoriasis:

(show top 50) (show all 3289)
# Title Authors Year
1
ARDS complicating pustular psoriasis: treatment with low-dose corticosteroids, vitamin C and thiamine. ( 29420246 )
2018
2
Efficacy of a polyphenolic extract from silver fir (<i>Abies alba</i>) bark on psoriasis: a randomised, double-blind, placebo-controlled trial. ( 29441952 )
2018
3
Increased psoriasis frequency in patients with familial Mediterranean fever. ( 29363386 )
2018
4
Increased levels of lipocalin 2 in palmoplantar pustular psoriasis. ( 29395573 )
2018
5
[EXPRESS] Quantitative Evaluation to Efficacy and Safety of Therapies for Psoriasis: A Network Meta-Analysis. ( 29448914 )
2018
6
Relationship between etanercept and thyroid function in patients with psoriasis vulgaris. ( 29440950 )
2018
7
In response to Lebwohl etA al, "Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials". ( 29447687 )
2018
8
Pustular psoriasis and related pustular skin diseases. ( 29333670 )
2018
9
Effect of an Educational and Psychological Intervention on Knowledge and Quality of Life among Patients with Psoriasis. ( 29441294 )
2018
10
Assessing the Importance of Treatment Goals in Patients with Psoriasis: Analytic Hierarchy Process vs. Likert Scales. ( 29450833 )
2018
11
Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. ( 29442137 )
2018
12
Treatment changes in patients with psoriasis on etanercept or adalimumab: a retrospective chart review. ( 29448850 )
2018
13
Novel methotrexate soft nanocarrier/fractional erbium YAG laser combination for clinical treatment of plaque psoriasis. ( 29448838 )
2018
14
Fissured tongue in patients with psoriasis. ( 29332713 )
2018
15
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. ( 29425183 )
2018
16
Genetic background and therapeutic response in generalized pustular psoriasis patients treated with granulocyte and monocyte adsorption apheresis. ( 29380726 )
2018
17
Mycosis fungoides in patients with psoriasis: an ongoing issue. ( 29336316 )
2018
18
Lymphopenia and fumaric acid esters for psoriasis: a retrospective case series prompted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommendations. ( 29027699 )
2018
19
Secukinumab Demonstrates High Sustained Efficacy and a Favorable Safety Profile in Patients with Moderate to Severe Psoriasis through 5 Years of Treatment (SCULPTURE Extension Study). ( 29444376 )
2018
20
Generalized pustular psoriasis triggered by Zika virus infection. ( 29027743 )
2018
21
Increased risk of psoriasis following scabies infection: A nationwide population-based matched-cohort study. ( 29356052 )
2018
22
Reply to: "Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials". ( 29447688 )
2018
23
Targeting IL-23 in psoriasis: current perspectives. ( 29441315 )
2018
24
Safety of biologic agents for psoriasis in patients with viral hepatitis. ( 29345515 )
2018
25
Branch Duct-type Intraductal Papillary Mucinous Neoplasm Presenting as Paraneoplastic Small Plaque Para-psoriasis. ( 29441297 )
2018
26
An audit of compliance with tuberculosis screening prior to treatment with biologics in psoriasis. ( 29446475 )
2018
27
Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. ( 29380251 )
2018
28
Clinical experience of adalimumab in the treatment of psoriasis - A 10-year journey in a tertiary dermatology centre. ( 29451193 )
2018
29
Infectious risk of biological drugs versus traditional systemic treatments in moderate to severe psoriasis: a cohort analysis in the French insurance database. ( 29446857 )
2018
30
Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis. ( 28967976 )
2018
31
A dramatic response to a single dose of infliximab in a patient with prolonged pustular psoriasis derived from inverse psoriasis. ( 28419647 )
2017
32
Association between mean platelet volume and disease severity in patients with psoriasis and psoriatic arthritis. ( 28507491 )
2017
33
Cyr61/CCN1 is involved in the pathogenesis of psoriasis vulgaris via promoting IL-8 production by keratinocytes in a JNK/NF-I_B pathway. ( 27856305 )
2017
34
Pediatric pustular psoriasis responsive to cyclosporine bridged to etanercept: A treatment approach. ( 29447638 )
2017
35
Overexpression of Psoriasin (S100A7) Contributes to Dysregulated Differentiation in Psoriasis. ( 27958610 )
2017
36
Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. ( 28071837 )
2017
37
Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis. ( 28522048 )
2017
38
Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report. ( 29196889 )
2017
39
CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells. ( 28389593 )
2017
40
Generalised pustular psoriasis and neutrophilic cholangitis: An infrequently reported association with excellent response to tumour necrosis factor inhibitors. ( 28195322 )
2017
41
CARD14-Mediated Activation of Paracaspase MALT1 in Keratinocytes: Implications for Psoriasis. ( 27939769 )
2017
42
Umbilical Psoriasis versus Tinea Corporis in Infants: A Simple Clinical Diagnosis/Image View. ( 28302469 )
2017
43
Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis. ( 27864793 )
2017
44
Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. ( 28944515 )
2017
45
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. ( 28076860 )
2017
46
Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study. ( 28293449 )
2017
47
Severe pellagra masked by concurrent plaque psoriasis: a case report of a hidden diagnosis. ( 28537863 )
2017
48
Bullous pemphigoid with IgG autoantibodies to the I+3 subunit of laminin 332 associated with psoriasis vulgaris. ( 28468743 )
2017
49
Case of recurrent severe cellulitis and cutaneous candidiasis during psoriasis treatment with ustekinumab. ( 28432713 )
2017
50
Two Cases of Successful Treatment of Refractory Chronic Inflammatory Skin Disease, Atopic Dermatitis and Psoriasis with Oral Alitretinoin. ( 28761307 )
2017

Variations for Psoriasis

Copy number variations for Psoriasis from CNVD:

7 (show all 27)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 107130 17 1225928 31649829 Copy number CCL3L3 Psoriasis
2 107139 17 1225928 31649843 Copy number CCL3L1 Psoriasis
3 107160 17 1242109 31665953 Copy number CCL4L2 Psoriasis
4 110229 17 31562580 31665959 Copy number CCL4L1 Psoriasis
5 209406 6 2614953 31491069 Copy number MICA Psoriasis
6 211355 6 32593131 32665540 Copy number HLA-DRB5 Psoriasis
7 212281 6 3674895 32665540 Copy number HLA-DRB1 Psoriasis
8 212427 6 3795995 32719407 Copy number HLA-DQA1 Psoriasis
9 212447 6 3813334 32742444 Copy number HLA-DQB1 Psoriasis
10 230703 8 1 12700000 Copy number Psoriasis
11 241415 8 6200000 12700000 Copy number Psoriasis
12 241416 8 6200000 12700000 Copy number DEFB103 Psoriasis
13 241417 8 6200000 12700000 Copy number DEFB104 Psoriasis
14 241418 8 6200000 12700000 Copy number DEFB4 Psoriasis
15 241438 8 6200000 12700000 Gain DEFB103 Psoriasis
16 241439 8 6200000 12700000 Gain DEFB104 Psoriasis
17 241440 8 6200000 12700000 Gain DEFB105 Psoriasis
18 241441 8 6200000 12700000 Gain DEFB106 Psoriasis
19 241442 8 6200000 12700000 Gain DEFB107 Psoriasis
20 241443 8 6200000 12700000 Gain DEFB4 Psoriasis
21 241446 8 6200000 12700000 Gain SPAG11 Psoriasis
22 241447 8 6200000 12700000 High copy numbers Psoriasis
23 241468 8 6200000 12700000 Copy number DEFB4 Psoriasis
24 242595 8 7292685 7758729 Large repeat SPAG11 Psoriasis
25 242629 8 7327435 7723985 Large repeat DEFB106 Psoriasis
26 242645 8 7332652 7718770 Large repeat DEFB105 Psoriasis
27 242649 8 7340777 7710648 Large repeat DEFB107 Psoriasis

Expression for Psoriasis

LifeMap Discovery
Genes differentially expressed in tissues of Psoriasis patients vs. healthy controls: 35 (show all 41)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 S100A9 S100 calcium binding protein A9 Skin + 7.14 0.000
2 S100A7 S100 calcium binding protein A7 Skin + 7.06 0.000
3 S100A7A S100 calcium binding protein A7A Skin + 6.53 0.000
4 S100A8 S100 calcium binding protein A8 Skin + 6.48 0.000
5 SPRR2F small proline-rich protein 2F Skin + 6.27 0.000
6 PI3 peptidase inhibitor 3, skin-derived Skin + 6.19 0.000
7 KRT6C keratin 6C, type II Skin + 5.98 0.000
8 SPRR2A small proline-rich protein 2A Skin + 5.97 0.000
9 KRT6A keratin 6A, type II Skin + 5.90 0.000
10 SPRR2B small proline-rich protein 2B Skin + 5.41 0.000
11 KRT6B keratin 6B, type II Skin + 5.39 0.000
12 SPRR2D small proline-rich protein 2D Skin + 5.35 0.000
13 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 Skin + 5.23 0.000
14 GJB2 gap junction protein, beta 2, 26kDa Skin + 4.97 0.000
15 SPRR2C small proline-rich protein 2C (pseudogene) Skin + 4.90 0.000
16 C10orf99 chromosome 10 open reading frame 99 Skin + 4.46 0.000
17 LCE3D late cornified envelope 3D Skin + 4.42 0.000
18 SPRR1A small proline-rich protein 1A Skin + 4.34 0.000
19 LCE3A late cornified envelope 3A Skin + 4.34 0.000
20 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) Skin + 4.33 0.000
21 SPRR1B small proline-rich protein 1B Skin + 4.29 0.000
22 KRT16 keratin 16, type I Skin + 4.27 0.000
23 KYNU kynureninase Skin + 4.26 0.000
24 LCN2 lipocalin 2 Skin + 4.20 0.000
25 SPRR2G small proline-rich protein 2G Skin + 4.12 0.000
26 LCE3E late cornified envelope 3E Skin + 4.12 0.000
27 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 Skin + 3.97 0.000
28 FABP5 fatty acid binding protein 5 (psoriasis-associated) Skin + 3.89 0.000
29 IFI27 interferon, alpha-inducible protein 27 Skin + 3.80 0.000
30 TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) Skin + 3.73 0.000
31 FABP5P2 fatty acid binding protein 5 pseudogene 2 Skin + 3.72 0.000
32 KLK6 kallikrein-related peptidase 6 Skin + 3.54 0.000
33 IL36G interleukin 36, gamma Skin + 3.50 0.000
34 DEFB103B defensin, beta 103B Skin + 3.46 0.000
35 PAMR1 peptidase domain containing associated with muscle regeneration 1 Skin - 3.43 0.000
36 GJB6 gap junction protein, beta 6, 30kDa Skin + 3.38 0.000
37 SPRR2E small proline-rich protein 2E Skin + 3.24 0.000
38 POSTN periostin, osteoblast specific factor Skin - 3.14 0.000
39 CD36 CD36 molecule (thrombospondin receptor) Skin + 3.12 0.000
40 IGFL1 IGF-like family member 1 Skin + 3.11 0.000
41 CACNA1H calcium channel, voltage-dependent, T type, alpha 1H subunit Skin - 3.11 0.000
Search GEO for disease gene expression data for Psoriasis.

Pathways for Psoriasis

GO Terms for Psoriasis

Biological processes related to Psoriasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of interleukin-6 production GO:0032715 9.26 IL36RN TNF
2 positive regulation of osteoclast differentiation GO:0045672 9.16 IL20 TNF
3 epidermis development GO:0008544 9.13 CDSN FABP5 KRT17
4 positive regulation of hair follicle development GO:0051798 8.62 KRT17 TNF

Sources for Psoriasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....